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Many existing and emerging consumer health technologies could have various applications in health 
promotion and disease prevention within the general population, and in supporting chronic disease 
management among patients. However, as Dr Cambon points out in her viewpoint (Linda Cambon’s 
viewpoint article) there are still many unanswered questions in relation to adopting a new model for 
disease prevention based on smart devices and applications (SDApps). One additional point that 
deserves attention is the regulatory oversight of health SDApps. 
Regulation of medical and consumer SDApps  
Health technologies based on SDApps can be divided into medical and consumer technologies based 
on their intended functionality. It is important to note that the intended functionality is defined by the 
manufacturer of the SDApp, not the end-user of the SDApp. If the manufacturer expresses e.g. 
through labelling or marketing statements that the intended use of an SDApp is for prevention of a 
disease, then the SDApp is likely to fall into the category of medical devices, and it will be regulated 
and monitored accordingly.  
Manufacturers of medical devices in Europe and the US need to establish not only premarket 
conformity with the corresponding regulations before the device can be marketed, but also ensure 
post-market surveillance for harms and adverse effects throughout the lifecycle of the product.[1] The 
burden of proof for showing the safety, technical performance, and efficacy of a medical device is on 
the manufacturer. However, if the manufacturer does not explicitly indicate an intended medical use 
for the SDApp e.g. for preventing or managing a disease, these regulations do not apply and the 
device is regulated as a consumer product. Within the European Economic Community, consumer 
products are only regulated for their technical safety (through the CE-marking) and for misleading 
and false marketing statements. In other words, for consumer health SDApps there is currently no 
risk-based assessment regulations that would take into account the potential risks of using a given 
SDApp technology for its intended purpose. Furthermore, changes made to consumer technologies, 
such as software updates, are not monitored similarly as those for medical devices, which means that 
the functionality and performance of the SDApp can change considerably during its lifecycle without 
clear documentation. 
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Consumer health technology assessment 
Before physicians start recommending or even prescribing consumer health technologies to patients 
we need to make sure that the current shortcomings of formal regulation of consumer health 
technologies are not going to be a threat to patient safety. Although the manufacturers of consumer 
health technologies are not making explicit medical claims, i.e. the intended use of a technology is not 
defined as medical by the manufacturer, the actual use and the motivation for using a given 
technology may be medical for the user of the technology. Clinicians have already used consumer 
technologies in making clinical decisions,[2, 3] and for many consumers the motivation for 
monitoring health-related parameters is self-improvement; as exemplified by the Quantified-Self and 
Biohacking movements.  
Therefore, the scientific community should respond to these needs by developing standards for 
appraising consumer health technologies parallel to medical technologies. Similar to that of formal 
health technology assessment it needs to take into account the benefits, risks, and costs related to 
using a particular consumer health technology for solving a given health problem. In particular, this 
assessment needs to take into account the risks involved if a consumer health technology fails to 
function as intended, and whether there are any potential unintended consequences of using the 
technology.[4] Developing a European accreditation system for manufacturer quality management 
systems covering the lifecycle of the consumer health technology could be one option to promote the 
uptake of voluntary conformity to standards and recommendations. 
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